Updated Clinical Data on X-396

The reported research found that the objective response rate was 88% (7/8) in ALK-TKI treatment-naïve patients, and 84% (10/12) in crizotinib-resistant patients.

http://www.cbs19.tv/story/30920448/xcovery-announces-updated-clinical-data-on-x-396-in-patients-with-alk-non-small-cell-lung-cancer-at-the-4th-aacr-iaslc-international-joint-conference

This entry was posted in Lung cancer, Potential Treatments, Research, Resistance to treatment, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply